SCHEMBL3230271

SCHEMBL3230271

[NaH].c1ccc2cccc-2cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.82
TAAR1 Q96RJ0 2/20 0.53
MAPK1 P28482 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
HSD17B10 Q99714 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
NOTUM Q6P988 1/20 0.53
MMP3 P08254 1/20 0.53
BCL2L1 Q07817 1/20 0.53
MAOA P21397 1/20 0.53
RAB9A P51151 3/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
ATM Q13315 1/20 0.47
SLC22A2 O15244 1/20 0.47
SLC22A1 O15245 1/20 0.47
SLC22A3 O75751 1/20 0.47
SLC6A4 P31645 1/20 0.47
NPC1 O15118 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biphenyl SCHEMBL10622486 0.95 ALDH1A1 (0.90) ALDH1A1TAAR1MAPK1CYP1A2CYP3A4
Biphenyl SCHEMBL29185389 0.95 ALDH1A1 (0.90) ALDH1A1TAAR1MAPK1CYP1A2CYP3A4
Benzene SCHEMBL6754211 0.95 ALDH1A1 (0.90) ALDH1A1TAAR1MAPK1CYP1A2CYP3A4
SCHEMBL2468018 0.95 ALDH1A1 (0.90) ALDH1A1TAAR1MAPK1CYP1A2CYP3A4
Biphenyl SCHEMBL1198500 0.95 ALDH1A1 (0.90) ALDH1A1TAAR1MAPK1CYP1A2CYP3A4
SCHEMBL8463 0.95 ALDH1A1 (0.90) ALDH1A1TAAR1MAPK1CYP1A2CYP3A4
Hydrochloric Acid SCHEMBL5731497 0.91 ALDH1A1 (0.82) ALDH1A1TAAR1MAPK1CYP1A2CYP3A4
Methane SCHEMBL9326425 0.91 ALDH1A1 (0.82) ALDH1A1TAAR1MAPK1CYP1A2CYP3A4
Ammonia Solution, Strong SCHEMBL28811288 0.91 ALDH1A1 (0.82) ALDH1A1TAAR1MAPK1CYP1A2CYP3A4
Biphenyl SCHEMBL2722776 0.91 ALDH1A1 (0.82) ALDH1A1TAAR1MAPK1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9376382-B2 N-substituted isopropyldimethyl azulene sulfonamide derivatives, and preparation method and use thereof SICHUAN GUOKANG PHARMACEUTICAL CO., LTD. (CN) 2016-06-28 US claimed
CN-103385863-B Sodium azulene sulfonate sustained-release preparation Sichuan guokang pharmaceutical co ltd 2015-07-15 CN claimed
US-20140206741-A1 N-SUBSTITUTED ISOPROPYLDIMETHYL AZULENE SULFONAMIDE DERIVATIVES, AND PREPARATION METHOD AND USE THEREOF SICHUAN GUOKANG PHARMACEUTICAL CO., LTD (CN) 2014-07-24 US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 US claimed
JP-11302196-A None JP disclosed
JP-11302196-A None JP disclosed
US-20250228887-A1 OPHTHALMIC COMPOSITION ROHTO PHARMACEUTICAL CO., LTD. (JP) 2025-07-17 US disclosed
CN-120053302-A Oral composition 狮王株式会社 2025-05-30 CN disclosed
CN-120053301-A Oral composition 狮王株式会社 2025-05-30 CN disclosed
CN-120053299-A Oral composition 狮王株式会社 2025-05-30 CN disclosed
US-12161652-B2 Anionic drug-containing ophthalmic device SEED CO., LTD. (JP) 2024-12-10 US disclosed
CN-119015243-A Preparation method of sodium azulene sulfonate tablet with stable storage and long-acting release 山东华素制药有限公司 2024-11-26 CN disclosed
CN-103385863-A Sodium azulene sulfonate sustained-release preparation Sichuan guokang pharmaceutical co ltd 2013-11-13 CN disclosed
CN-103385863-A Sodium azulene sulfonate sustained-release preparation Sichuan guokang pharmaceutical co ltd 2013-11-13 CN disclosed
US-20100069323-A1 COMPOSITION FOR APPLICATION TO SKIN OR MUCOSA ROHTO PHARMACEUTICAL CO., LTD. (JP) 2010-03-18 US disclosed
CN-1561986-A Capsule agent containing L-glutamine and azulene sodium solfonate ZHANG HONGJUN (CN) 2005-01-12 CN disclosed
JP-H11302196-A SODIUM AZULENE SULFONATE-CONTAINING PREPARATION SUMITOMO PHARMACEUT CO LTD 1999-11-02 JP disclosed
JP-H11302196-A SODIUM AZULENE SULFONATE-CONTAINING PREPARATION SUMITOMO PHARMACEUT CO LTD 1999-11-02 JP disclosed
EP-0147915-B1 NEW AZULENE DERIVATIVES USEFUL AS ANTI-ULCERATIVE AND ANTI-FLAMMATORY AGENTS Kotobuki Seiyaku Co., Ltd. (JP) 1987-05-06 EP disclosed
EP-0147915-A1 New azulene derivatives useful as anti-ulcerative and anti-flammatory agents Kotobuki Seiyaku Co., Ltd. (JP) 1985-07-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140206741-A1 N-SUBSTITUTED ISOPROPYLDIMETHYL AZULENE SULFONAMIDE DERIVATIVES, AND PREPARATION METHOD AND USE THEREOF GIPR, SSTR5, STS ALDH1A1 244/4885TAAR1 901/4885MAPK1 3525/4885
US-12161652-B2 Anionic drug-containing ophthalmic device ACMSD, UACA, ADSL ALDH1A1 2770/4885TAAR1 1261/4885MAPK1 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.